fatido JPMorgan Chase ( JPM ) expects that markets revenue will rise in the mid-teens. "We're hopeful for the quarter," Troy Rohrbaugh, co-CEO of the Commercial & Investment Bank, said at the company's 2026 investor update. "It started out well." "We started the year strong. Pipelines are very strong," added Doug Petno, co-CEO of the Commercial & Investment Bank. In private equity, "they have trem...
fatido JPMorgan Chase ( JPM ) expects that markets revenue will rise in the mid-teens. "We're hopeful for the quarter," Troy Rohrbaugh, co-CEO of the Commercial & Investment Bank, said at the company's 2026 investor update. "It started out well." "We started the year strong. Pipelines are very strong," added Doug Petno, co-CEO of the Commercial & Investment Bank. In private equity, "they have tremendous dry powder" and are looking to invest, even though there's some frustration in monetization of investments, Petno added. "I'm shocked that people are shocked," Rohrbaugh said in discussing the recent private credit turmoil, adding that JPMorgan has prepared for that possibility. "There's still lots of capital in the private capital ecosystem," he noted. Petno emphasized that the bank advises its clients with its focus on returns rather than an investment type. Mary Callahan Erdoes, CEO of Asset & Wealth Management, said her division is always looking at potential acquisitions. The company had looked at all the potential big deals in her sector but turned down most of them because they didn't fit with JPMorgan. The company always needs to consider whether it's better to build a business from scratch or acquire an existing business. JPMorgan ( JPM ) is in the early stages of expanding internationally, said Marianne Lake, CEO of the Consumer & Community Bank. Chase's consumer bank in the U.K. now has 2.8M customers with $35B of deposits. The company is set to enter Germany in Q2. "We're in early, early days. We have very, very good momentum," she said. Earlier, JPMorgan's chief financial officer, Jeremy Barnum, said the macro backdrop remains supportive while the consumer continues to be resilient. More on JPMorgan Chase JPMorgan Chase: Common And Preferred Shares Diverge In 2026 JPMorgan Chase & Co. (JPM) Presents at UBS Financial Services Conference 2026 Transcript JPMorgan: An Attractive Long-Term Idea For Income And Capital Gains JPMorgan Chase remains 'cautiously o...
Nio (NYSE:NIO), designs and sells electric vehicles, including sedans and SUVs. The stock closed Monday at $5.29, up 4.34%, after the company reported a record 1 million battery swaps in less than a week during the Lunar New Year, and investors are watching for signs of sustained
Nio (NYSE:NIO), designs and sells electric vehicles, including sedans and SUVs. The stock closed Monday at $5.29, up 4.34%, after the company reported a record 1 million battery swaps in less than a week during the Lunar New Year, and investors are watching for signs of sustained
Novo Nordisk (NYSE:NVO), a healthcare giant that develops and markets diabetes and obesity treatments, closed Monday at $39.63, down 16.43%. The stock fell after it announced CagriSema, its next-generation obesity drug, had not fared well in a head-to-head trial.
Novo Nordisk (NYSE:NVO), a healthcare giant that develops and markets diabetes and obesity treatments, closed Monday at $39.63, down 16.43%. The stock fell after it announced CagriSema, its next-generation obesity drug, had not fared well in a head-to-head trial.
Is China Really Dumping US Treasuries? Authored by Lance Roberts via RealInvestmentAdvice.com, “China is dumping US Treasuries to get out of the dollar.” This claim has been circulating the mainstream feeds lately, with the narrative that the “end of the dollar is near,” or “the US will lose its funding base” and the “bond yields will surge.” But are those claims valid? Such is what we will explor...
Is China Really Dumping US Treasuries? Authored by Lance Roberts via RealInvestmentAdvice.com, “China is dumping US Treasuries to get out of the dollar.” This claim has been circulating the mainstream feeds lately, with the narrative that the “end of the dollar is near,” or “the US will lose its funding base” and the “bond yields will surge.” But are those claims valid? Such is what we will explore in more detail. Let’s start with the chart that has everyone concerned. As shown, China’s holdings of US Treasury bonds have fallen from nearly $1.2 trillion to $600 billion, or a 50% decline. On the surface, you can certainly understand the reasons for concern, as the decline in holdings over the last decade supports a clean storyline. However, the problem is the step between observation and conclusion. A lower line item for “China, Mainland” does not equal a forced sale, it does not prove intent, nor does it prove a structural exit. What it does show is a lack of understanding about the dynamics of reserve currency management, and, in the case of China, the need to protect those reserves. Let’s start with the Treasury Department, which states that the holdings tables are built “primarily on the basis of custodial data.” That phrase matters. Custodial data records where securities are held for settlement and safekeeping. Critically, the custodian is not the same as the beneficial owner, and that distinction undermines the headline narrative. The Treasury’s own FAQ is the most important in this particular narrative: “If a Treasury security purchased by a foreign resident is held in a custodial account in a third country, the true country of ownership will not be reflected.” Read that sentence again. The system is designed to track where the bonds sit, not whose balance sheet carries the risk. This is crucially important when it comes to the narrative that China is dumping its bond holdings and moving away from the dollar. For those jumping to that conclusion, they did not...
Nemes Laszlo/iStock via Getty Images Vir Biotechnology ( VIR ) is up ~55% in after-hours trading following an announcement it is in a development and commercialization deal with Astellas Pharma ( ALPMF ) for the CD3 T-cell engager VIR-5500 for metastatic castration-resistant prostate cancer. Terms call for Astellas ( ALPMY ) to pay $335M in upfront and near-term milestone payments. Vir is eligible...
Nemes Laszlo/iStock via Getty Images Vir Biotechnology ( VIR ) is up ~55% in after-hours trading following an announcement it is in a development and commercialization deal with Astellas Pharma ( ALPMF ) for the CD3 T-cell engager VIR-5500 for metastatic castration-resistant prostate cancer. Terms call for Astellas ( ALPMY ) to pay $335M in upfront and near-term milestone payments. Vir is eligible for up to $1.37B in development, regulatory, and sales milestones, as well as tiered, double-digit royalties on sales outside the US. Astellas has exclusive rights to commercialize VIR-5500 outside the US as well as lead commercialization in the US. Vir is responsible for 40% of future development costs, with Astellas covering the remaining 60%. Updated phase 1 monotherapy results on VIR-5500 released Monday found dose-dependent anti-tumor activity, with 82% PSA50 and 53% PSA90 declines, and RECIST-evaluable objective responses (45% ORR in 5/11 patients) in ≥3,000 µg/kg in cohorts dosed every three weeks. More on Vir Biotechnology Vir Biotechnology: The Low-Down On The Readouts Ahead Vir Biotechnology, Inc. (VIR) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow Vir Biotechnology, Inc. (VIR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript Vir Biotechnology GAAP EPS of -$0.31 beats by $0.10, revenue of $64.07M beats by $44.16M Vir Biotechnology Q4 2025 Earnings Preview
Christoph Burgstedt/iStock via Getty Images Shares of Cullinan Therapeutics ( CGEM ) have risen by 31% year-to-date, yet are down 70% over the past five years. I decided to accumulate a position in the company in late December, taking advantage of the post-ASH selloff, as I found their dual-pronged strategy of pursuing cancer and autoimmune disease to be attractive, along with highly capable, BD-s...
Christoph Burgstedt/iStock via Getty Images Shares of Cullinan Therapeutics ( CGEM ) have risen by 31% year-to-date, yet are down 70% over the past five years. I decided to accumulate a position in the company in late December, taking advantage of the post-ASH selloff, as I found their dual-pronged strategy of pursuing cancer and autoimmune disease to be attractive, along with highly capable, BD-savvy management. Cullinan has largely decided to go all-in on the T-cell engager modality, with every molecule in the pipeline being first or best-in-class, having shown monotherapy efficacy and addressing a well-validated target and large market opportunity. Early ASH results for CLN-049 portend it becoming "the next menin, " in my opinion (with the usual caveats for a low number of patients and longer follow-up needed). Unlike other areas of biotech experiencing regulatory uncertainty, the bar is quite clear in AML, where 049's 30% composite CR rate in dose escalation compares favorably to anything approved in the past six to seven years, and there's a clear path to market via a single-arm study for accelerated approval. Also, I note that there are no other anti-FLT3 T cell engagers in development (scarcity of value). As for the CD19xCD3 program, Merck paying $700M upfront for China-based Curon Biopharmaceuticals' CN201 gives us a comp showing Cullinan undervalued on this asset alone despite having a lead in the clinic in the US. The big idea here is to match the potency of CAR-T with the flexibility of redosing and subcutaneous administration (broad applicability, starting with a post-biologic pre-CAR-T setting, then moving earlier to displace biologics). I believe the company is still a great option for investors looking for clinical-stage exposure in biotech, so let's dig a bit deeper together to see whether readers agree with my assessment. Chart Finviz Figure 1: CGEM weekly chart (Source: Finviz ) In the weekly chart above, we can see shares spiked to the mid-$20s in...
PayPal (NASDAQ:PYPL), a digital payments platform for merchants and consumers worldwide, closed Monday at $44.05, up 5.76%. The stock climbed after reports of unsolicited takeover interest, and investors are watching for any formal M&A proposals or responses from the board. T
PayPal (NASDAQ:PYPL), a digital payments platform for merchants and consumers worldwide, closed Monday at $44.05, up 5.76%. The stock climbed after reports of unsolicited takeover interest, and investors are watching for any formal M&A proposals or responses from the board. T
JHVEPhoto/iStock Editorial via Getty Images Shares of The Chemours Company ( CC ) are up about 9% from last year, but this masks a tremendous amount of volatility with shares trading between $9 and $22. After a strong run, the stock plunged 17% last week in response to Q4 earnings that were weaker than expected. While the company’s new Opteon product is gaining traction and data centers offer incr...
JHVEPhoto/iStock Editorial via Getty Images Shares of The Chemours Company ( CC ) are up about 9% from last year, but this masks a tremendous amount of volatility with shares trading between $9 and $22. After a strong run, the stock plunged 17% last week in response to Q4 earnings that were weaker than expected. While the company’s new Opteon product is gaining traction and data centers offer incremental demand opportunities, the underlying macro backdrop is still difficult. Frankly, I view this reaction as partly due to the fact shares simply got ahead of themselves. I last covered CC in November , rating shares a "B uy," and even with the post-earnings drop, they have rallied nearly 40%. This has justified my rating, but shares have surpassed my $16-$17 target. With updated financials, now is a good time to revisit Chemours. Seeking Alpha In the company’s fourth quarter , Chemours earned $0.05 per share, which was $0.02 below expectations as revenue declined by 2% to $1.33 billion. Adjusted EBITDA declined by $40 million from last year to $128 million. EBITDA was significantly pressured by the fact that lower volumes reduce the efficiency of its plants, increasing per-unit costs and weakening margins. CC also took a noncash charge on inventories to recognize the weak macro environment. Essentially, solid results in its refrigerant business are being offset by weakness in its more exposed units. Chemours Refrigerants Were Strong; Other Units Were Weak Titanium Technologies' (“TT”) sales dropped 11% to $562 million. Prices were down 6%, and EBITDA fell by 67% to just $23 million. In December, it increased prices on TiO2, which should help to lift results in 2026. EBITDA margins are now down to just 4%. Pricing overseas in Asia was particularly weak. TiO2 is a key input into paint, making construction and auto sector activity key variables. Activity across both industries has been weak, partially due to the elevated rate environment, as well as going structural weake...
ProAssurance press release ( PRA ): Q4 GAAP EPS of $0.82 beats by $0.61 . Revenue of $269.64M (-7.1% Y/Y) beats by $8.56M . More on ProAssurance Seeking Alpha’s Quant Rating on ProAssurance Historical earnings data for ProAssurance Financial information for ProAssurance
ProAssurance press release ( PRA ): Q4 GAAP EPS of $0.82 beats by $0.61 . Revenue of $269.64M (-7.1% Y/Y) beats by $8.56M . More on ProAssurance Seeking Alpha’s Quant Rating on ProAssurance Historical earnings data for ProAssurance Financial information for ProAssurance